dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 688-698

  McAllister, Florencia ^a   Pineda, Danielle M ^b   Jimbo, Masaya ^b   Lal, Shruti ^b   Burkhart, Richard A ^b   Moughan, Jennifer ^c   Winter, Kathryn A ^c   Abdelmohsen, Kotb ^d   Gorospe, Myriam ^d   De Jesus Acosta, Ana ^a   Lankapalli, Rachana H ^a   Winter, Jordan M ^b   Yeo, Charles J ^b   Witkiewicz, Agnieska K ^e   Iacobuzio Donahue, Christine A ^a   Laheru, Daniel ^a   Brody, Jonathan R ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c RTOG Statistical Center   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; dCK; Gemcitabine; HuR; Pancreatic cancer

Indexed keywords

ANTIGEN; DEOXYCYTIDINE KINASE; FLUOROURACIL; GEMCITABINE; HUMAN ANTIGEN R; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; ELAVL1 PROTEIN, HUMAN; HU ANTIGEN;

ADJUVANT CHEMORADIOTHERAPY; ARTICLE; CARCINOMA CELL; CELL CULTURE; CELLS; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SENSITIVITY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, PANCREATIC DUCTAL; CELL NUCLEUS; CHEMORADIOTHERAPY; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL NUCLEUS; CHEMORADIOTHERAPY; CYTOPLASM; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DISEASE-FREE SURVIVAL; FLUOROURACIL; FOLLOW-UP STUDIES; GENE EXPRESSION; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901704779     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28413     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
2. Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). GI ASCO, 2012.
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/ NEJMoa1011923
4. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, et al. 1423 pancreaticoduode- nectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg 2006; 10:1199-210, discussion 1210-1; PMID:17114007; http://dx.doi.org/10. 1016/j.gassur.2006.08.018
5. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77; PMID:17227978; http://dx.doi.org/10.1001/jama.297.3.267
6. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, et al.; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304:1073-81; PMID:20823433; http://dx.doi.org/10.1001/jama. 2010.1275
7. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019-26; PMID:18319412; http://dx.doi.org/10.1001/jama.299.9.1019
8. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899-903; PMID:4015380; http://dx.doi.org/10.1001/archsurg.1985.01390320023003
9. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO. 2011.36.5742
10. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 2004; 4:8; PMID:15157282; http://dx.doi.org/10.1186/1471-2210-4-8
11. Bergman AM, Pinedo HM, Jongsma AP, Brouwer M, Ruiz van Haperen VW, Veerman G, Leyva A, Eriksson S, Peters GJ. Decreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 1999; 57:397-406; PMID:9933028; http://dx.doi.org/10.1016/S0006-2952(98)00318-9
12. Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013; 31:4453-61; PMID:24220555; http://dx.doi.org/10.1200/JCO.2013.51.0826
13. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58:4349-57; PMID:9766663
14. Bouffard DY, Laliberté J, Momparler RL. Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 1993; 45:1857-61; PMID:8494545; http://dx.doi.org/10.1016/0006-2952(93)90444-2
15. Sebastiani V, Ricci F, Rubio-Viqueira B, Kulesza P, Yeo CJ, Hidalgo M, Klein A, Laheru D, Iacobuzio-Donahue CA. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 2006; 12:2492-7; PMID:16638857; http://dx.doi.org/10.1158/1078-0432.CCR-05-2655
16. Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR. The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69:4567-72; PMID:19487279; http://dx.doi.org/10.1158/0008-5472.CAN-09-0371
17. Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, et al. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg 2010; 252:499-505, discussion 505-6; PMID:20739850
18. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957; 179:663-6; PMID:13418758; http://dx.doi.org/10.1038/179663a0
19. Brody JR, Hucl T, Costantino CL, Eshleman JR, Gallmeier E, Zhu H, van der Heijden MS, Winter JM, Wikiewicz AK, Yeo CJ, et al. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009; 69:984-91; PMID:19155291; http://dx.doi.org/10.1158/0008-5472. CAN-08-3610
20. Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther 2008; 7:986-94; PMID:18443433; http://dx.doi.org/10.4161/cbt.7.7.6181
21. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8; PMID:12724731; http://dx.doi.org/10.1038/nrc1074
22. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6:1653-64; PMID:3049954
23. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587:194-205; PMID:12084461; http://dx.doi.org/10.1016/S0925-4439(02) 00082-0
24. Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009; 136:187-95; PMID:18992248; http://dx.doi.org/10. 1053/j.gastro.2008.09.067
25. Pérez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M, Mazo A. Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008; 76:322-9; PMID:18589402; http://dx.doi.org/10.1016/j.bcp.2008.05.011
26. Akita H, Zheng Z, Takeda Y, Kim C, Kittaka N, Kobayashi S, Marubashi S, Takemasa I, Nagano H, Dono K, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene 2009; 28:2903-9; PMID:19543324; http://dx.doi.org/10.1038/onc.2009.158
27. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, Hines OJ, Reber H, Seligson DB, Horvath S, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 2010; 28:1358-65; PMID:20142597; http://dx.doi.org/10.1200/JCO.2009.24.5639
28. Farrell JJ, Bae K, Wong J, Guha C, Dicker AP, Elsaleh H. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 2012; 12:395-403; PMID:21625252; http://dx.doi.org/10.1038/tpj.2011.22
29. Masuda K, Abdelmohsen K, Kim MM, Srikantan S, Lee EK, Tominaga K, Selimyan R, Martindale JL, Yang X, Lehrmann E, et al. Global dissociation of HuR-mRNA complexes promotes cell survival after ionizing radiation. EMBO J 2011; 30:1040-53; PMID:21317874; http://dx.doi.org/10.1038/emboj.2011.24
30. Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, et al. HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Res 2014; 74:1128-40; PMID:24536047; http://dx.doi.org/10.1158/ 0008-5472.CAN-13-1915
31. Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr., Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58:1149-58; PMID:9515799
32. Askmalm MS, Carstensen J, Nordenskjöld B, Olsson B, Rutqvist LE, Skoog L, Stål O. Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients. Acta Oncol 2004; 43:235-44; PMID:15244246; http://dx.doi.org/10.1080/02841860410029474
33. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997; 57:1769-75; PMID:9135021
34. Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U, Herrmann R, Rochlitz C. STRAP is a strong predictive marker of adjuvant chemotherapy benefit in colorectal cancer. Neoplasia 2004; 6:813-20; PMID:15720808; http://dx.doi.org/10.1593/neo.04307
35. Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, et al.; Italian Oncology Group for Clincal Research. HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results. Clin Breast Cancer 2005; 6:253-9; PMID:16137437; http://dx.doi.org/10.3816/CBC.2005. n.028
36. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002; 20:1721-8; PMID:11919227; http://dx.doi.org/10.1200/JCO.2002.07.039
37. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, et al. DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. Int J Cancer 2002; 102:254-7; PMID:12397645; http://dx.doi.org/10.1002/ijc.10711
38. Öhrling K, Karlberg M, Edler D, Hallström M, Ragnhammar P. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer. Clin Colorectal Cancer 2013; 12:128-35; PMID:23276521; http://dx.doi.org/10.1016/j.clcc.2012.11.003
39. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57; PMID:12867608; http://dx.doi.org/10.1056/NEJMoa022289
40. Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103:863-75; PMID:21597022; http://dx.doi.org/10.1093/jnci/djr153
41. Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ. Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 2000; 36:1974-83; PMID:11000580; http://dx.doi.org/10.1016/S0959-8049(00)00246-X
42. Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, et al. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol 2013; 10:1312-23; PMID:23807417; http://dx.doi.org/10.4161/rna.25274
43. López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2:11-3; PMID:17132932; http://dx.doi.org/10. 4161/rna.2.1.1552
44. Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M. miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci U S A 2008; 105:20297-302; PMID:19088191; http://dx.doi.org/10.1073/pnas.0809376106
45. Winter JM, Dixon DA, Brody JR. HuR. Springer, 2012.
46. Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, et al. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells. Cancer Biol Ther 2012; 13:946-55; PMID:22785201; http://dx.doi.org/10.4161/cbt. 20952
47. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, et al.; European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308:147-56; PMID:22782416; http://dx.doi.org/10.1001/jama. 2012.7352
48. Hatzis P, Al-Madhoon AS, Jüllig M, Petrakis TG, Eriksson S, Talianidis I. The intracellular localization of deoxycytidine kinase. J Biol Chem 1998; 273:30239-43; PMID:9804782; http://dx.doi.org/10.1074/jbc.273.46. 30239
49. Kuwano Y, Kim HH, Abdelmohsen K, Pullmann R Jr., Martindale JL, Yang X, Gorospe M. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol 2008; 28:4562-75; PMID:18490444; http://dx.doi.org/10.1128/MCB.00165-08
50. Kaplan EL, Meier P. Nonparameteric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81; http://dx.doi.org/10.1080/ 01621459.1958.10501452
51. Cox DR. Regression models and life-tables. J Roy Stat Soc B 1972; 34:187-220.